Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free THRD Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Third Harmonic Bio (THRD) Competitors

Third Harmonic Bio logo
Compare

THRD vs. PCRX, PHAT, CERT, ANNX, and SLS

Should you be buying Third Harmonic Bio stock or one of its competitors? The main competitors of Third Harmonic Bio include Pacira BioSciences (PCRX), Phathom Pharmaceuticals (PHAT), Certara (CERT), Annexon (ANNX), and SELLAS Life Sciences Group (SLS). These companies are all part of the "med - biomed/gene" industry.

How does Third Harmonic Bio compare to Pacira BioSciences?

Third Harmonic Bio (NASDAQ:THRD) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Pacira BioSciences has a net margin of 0.70% compared to Third Harmonic Bio's net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Third Harmonic Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Third Harmonic BioN/A -19.27% -18.67%
Pacira BioSciences 0.70%10.24%5.47%

Third Harmonic Bio has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

In the previous week, Pacira BioSciences had 21 more articles in the media than Third Harmonic Bio. MarketBeat recorded 21 mentions for Pacira BioSciences and 0 mentions for Third Harmonic Bio. Pacira BioSciences' average media sentiment score of 0.28 beat Third Harmonic Bio's score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company Overall Sentiment
Third Harmonic Bio Neutral
Pacira BioSciences Neutral

Pacira BioSciences has higher revenue and earnings than Third Harmonic Bio. Third Harmonic Bio is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Third Harmonic BioN/AN/A-$45.47M-$0.62N/A
Pacira BioSciences$726.41M1.34$7.03M$0.12206.58

Pacira BioSciences has a consensus target price of $29.40, suggesting a potential upside of 18.60%. Given Pacira BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Third Harmonic Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Third Harmonic Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Pacira BioSciences
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

94.0% of Third Harmonic Bio shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 7.8% of Third Harmonic Bio shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Pacira BioSciences beats Third Harmonic Bio on 13 of the 15 factors compared between the two stocks.

How does Third Harmonic Bio compare to Phathom Pharmaceuticals?

Third Harmonic Bio (NASDAQ:THRD) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Phathom Pharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 98.41%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Third Harmonic Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Third Harmonic Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Phathom Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Third Harmonic Bio has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

94.0% of Third Harmonic Bio shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 7.8% of Third Harmonic Bio shares are held by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Third Harmonic Bio has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Third Harmonic Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Third Harmonic BioN/A -19.27% -18.67%
Phathom Pharmaceuticals -76.77%N/A -44.29%

In the previous week, Phathom Pharmaceuticals had 17 more articles in the media than Third Harmonic Bio. MarketBeat recorded 17 mentions for Phathom Pharmaceuticals and 0 mentions for Third Harmonic Bio. Third Harmonic Bio's average media sentiment score of 0.00 beat Phathom Pharmaceuticals' score of -0.12 indicating that Third Harmonic Bio is being referred to more favorably in the media.

Company Overall Sentiment
Third Harmonic Bio Neutral
Phathom Pharmaceuticals Neutral

Third Harmonic Bio has higher earnings, but lower revenue than Phathom Pharmaceuticals. Third Harmonic Bio is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Third Harmonic BioN/AN/A-$45.47M-$0.62N/A
Phathom Pharmaceuticals$175.11M5.74-$221.25M-$2.12N/A

Summary

Phathom Pharmaceuticals beats Third Harmonic Bio on 9 of the 16 factors compared between the two stocks.

How does Third Harmonic Bio compare to Certara?

Third Harmonic Bio (NASDAQ:THRD) and Certara (NASDAQ:CERT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Third Harmonic Bio has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Certara has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.

Certara has a consensus price target of $10.44, indicating a potential upside of 69.00%. Given Certara's stronger consensus rating and higher possible upside, analysts plainly believe Certara is more favorable than Third Harmonic Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Third Harmonic Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Certara
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.46

Third Harmonic Bio has a net margin of 0.00% compared to Certara's net margin of -0.38%. Certara's return on equity of 4.20% beat Third Harmonic Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Third Harmonic BioN/A -19.27% -18.67%
Certara -0.38%4.20%2.90%

94.0% of Third Harmonic Bio shares are held by institutional investors. Comparatively, 74.0% of Certara shares are held by institutional investors. 7.8% of Third Harmonic Bio shares are held by insiders. Comparatively, 1.1% of Certara shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Certara had 6 more articles in the media than Third Harmonic Bio. MarketBeat recorded 6 mentions for Certara and 0 mentions for Third Harmonic Bio. Certara's average media sentiment score of 0.27 beat Third Harmonic Bio's score of 0.00 indicating that Certara is being referred to more favorably in the news media.

Company Overall Sentiment
Third Harmonic Bio Neutral
Certara Neutral

Certara has higher revenue and earnings than Third Harmonic Bio. Certara is trading at a lower price-to-earnings ratio than Third Harmonic Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Third Harmonic BioN/AN/A-$45.47M-$0.62N/A
Certara$418.84M2.26-$1.60M-$0.01N/A

Summary

Certara beats Third Harmonic Bio on 11 of the 16 factors compared between the two stocks.

How does Third Harmonic Bio compare to Annexon?

Third Harmonic Bio (NASDAQ:THRD) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Third Harmonic Bio has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Annexon has a consensus price target of $17.00, indicating a potential upside of 197.20%. Given Annexon's stronger consensus rating and higher possible upside, analysts plainly believe Annexon is more favorable than Third Harmonic Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Third Harmonic Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Annexon
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Third Harmonic Bio's return on equity of -19.27% beat Annexon's return on equity.

Company Net Margins Return on Equity Return on Assets
Third Harmonic BioN/A -19.27% -18.67%
Annexon N/A -101.33%-76.96%

94.0% of Third Harmonic Bio shares are held by institutional investors. 7.8% of Third Harmonic Bio shares are held by insiders. Comparatively, 12.7% of Annexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Annexon had 1 more articles in the media than Third Harmonic Bio. MarketBeat recorded 1 mentions for Annexon and 0 mentions for Third Harmonic Bio. Third Harmonic Bio's average media sentiment score of 0.00 equaled Annexon'saverage media sentiment score.

Company Overall Sentiment
Third Harmonic Bio Neutral
Annexon Neutral

Third Harmonic Bio is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Third Harmonic BioN/AN/A-$45.47M-$0.62N/A
AnnexonN/AN/A-$206.69M-$1.36N/A

Summary

Third Harmonic Bio and Annexon tied by winning 6 of the 12 factors compared between the two stocks.

How does Third Harmonic Bio compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Third Harmonic Bio (NASDAQ:THRD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

SELLAS Life Sciences Group has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500. Comparatively, Third Harmonic Bio has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 94.0% of Third Harmonic Bio shares are owned by institutional investors. 1.2% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 7.8% of Third Harmonic Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Third Harmonic Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.25N/A
Third Harmonic BioN/AN/A-$45.47M-$0.62N/A

SELLAS Life Sciences Group presently has a consensus price target of $10.00, indicating a potential upside of 105.34%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, equities analysts clearly believe SELLAS Life Sciences Group is more favorable than Third Harmonic Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Third Harmonic Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Third Harmonic Bio's return on equity of -19.27% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -63.06% -54.50%
Third Harmonic Bio N/A -19.27%-18.67%

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Third Harmonic Bio. MarketBeat recorded 3 mentions for SELLAS Life Sciences Group and 0 mentions for Third Harmonic Bio. SELLAS Life Sciences Group's average media sentiment score of 0.72 beat Third Harmonic Bio's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Overall Sentiment
SELLAS Life Sciences Group Positive
Third Harmonic Bio Neutral

Summary

SELLAS Life Sciences Group beats Third Harmonic Bio on 8 of the 13 factors compared between the two stocks.

Get Third Harmonic Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

THRD vs. The Competition

Export
MetricThird Harmonic BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$242.80M$3.40B$6.25B$11.77B
Dividend YieldN/A2.23%2.74%5.26%
P/E Ratio-4.3738.5729.2527.07
Price / SalesN/A280.02504.6873.47
Price / CashN/A125.0643.3053.90
Price / Book0.857.059.676.69
Net Income-$45.47M$23.62M$3.55B$332.64M

Third Harmonic Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THRD
Third Harmonic Bio
N/A$5.38
flat		N/AN/A$242.80MN/AN/AN/A
PCRX
Pacira BioSciences
3.2074 of 5 stars		$24.44
-4.1%		$29.40
+20.3%		N/A$961.35M$726.41M203.68720
PHAT
Phathom Pharmaceuticals
2.8843 of 5 stars		$12.01
+7.2%		$25.00
+108.2%		N/A$953.95M$175.11MN/A110
CERT
Certara
3.352 of 5 stars		$6.18
+0.8%		$10.44
+69.0%		N/A$947.55M$418.84MN/A1,576
ANNX
Annexon
1.8403 of 5 stars		$5.75
-2.0%		$17.00
+195.7%		N/A$934.42MN/AN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:THRD) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel